This is an AMP page which is for mobile devices.

View Non AMP page

Twitter

Link your Twitter Account to Market Wire News

When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.

Be alerted of any news about your stocks and see what other stocks are trending.

home / news releases / CTSO - Cytosorbents outlines plans for DrugSorb-ATR appeal and targets breakeven core business by second half 2025

CTSO - Cytosorbents outlines plans for DrugSorb-ATR appeal and targets breakeven core business by second half 2025

May, 14 2025 09:38 PM CytoSorbents Corporation

2025-05-14 21:38:35 ET

More on Cytosorbents

Cytosorbents Corporation (CTSO) Q1 2025 Earnings Call Transcript
Cytosorbents Corporation (CTSO) Q4 2024 Earnings Call Transcript
Cytosorbents Non-GAAP EPS of -$0.06, revenue of $8.73M misses by $0.28M
Cytosorbents outlines 2025 growth strategy with $1B market potential for DrugSorb-ATR
Seeking Alpha’s Quant Rating on Cytosorbents

For further details see:

Cytosorbents outlines plans for DrugSorb-ATR appeal and targets breakeven core business by second half 2025

Stock Information

Company Name:	CytoSorbents Corporation
Stock Symbol:	CTSO
Market:	NASDAQ
Website:	cytosorbents.com

Get CTSO Alerts

News, Short Squeeze, Breakout and More Instantly...

Market Wire News is a media platform, the information on this page was provided by SeekingAlpha via Quote Media. Read our full disclaimer.